Published: 04 March, 2021 | Volume 5 - Issue 1 | Pages: 005-034
Figure 3:
Schematic illustration of nanocarrier-mediated delivery of RNAi therapeutics: the biological barriers for gene silencing in cancer treatment include reaching the circulation, crossing the vascular barrier, cellular uptake, and endosomal escape. Following systemic administration in patients, the RNAi therapeutics could be transported to the blood vessels in tumor tissues. The gene vectors could escape from the sinusoidal and fenestrated capillaries and retain in the tumor regions. The gene vectors could be taken by cancer cells through endocytosis or ligand- mediated intracellular transport and then transferred into the cytoplasm to silence target genes for cancer therapy.
Read Full Article HTML DOI: 10.29328/journal.jro.1001035 Cite this Article Read Full Article PDF
HSPI: We're glad you're here. Please click "create a new Query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."